How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data

Heart

Volumn 97, Issue 21, 2011, Pages 1771-1775

  Lasserson, Daniel S ^a   Buclin, Thierry ^b   Glasziou, Paul ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c BOND UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETAXOLOL; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; ENALAPRIL; IMIDAPRIL; IRBESARTAN; ISRADIPINE; LISINOPRIL; LOSARTAN; METHYCLOTHIAZIDE; METOPROLOL; NICARDIPINE; NIFEDIPINE; PLACEBO; PRAZOSIN; RAMIPRIL; RILMENIDINE; SPIRAPRIL; TELMISARTAN; URAPIDIL;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 80053621508     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.221473     Document Type: Review

References (25)

1. British Cardiac Society, British Hypertension Society, Diabetes UK, et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.
2. Turnbull F; Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
4. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes TrialeBlood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. (Pubitemid 41265663)
5. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007;370:1432-42. (Pubitemid 47576154)
6. Lavallee PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007;6:953-60. (Pubitemid 47570023)
7. Swartz S, Gonasun L, McAllister R Jr, et al. A multicenter comparison of isradipine and prazosin for treatment of essential hypertension. Cardiovasc Drugs Ther 1990;4:413-17. (Pubitemid 20208390)
8. van der Does R, Euler R. Comparison of the antihypertensive effect of imadipril and enalapril in the treatment of mild to moderate essential hypertension: a randomized, double-blind, parallel-group study. Curr Ther Res Clin E 2001;62:437-50. (Pubitemid 32554518)
9. van der Does R, Euler R. Parallel -group study to compare the anti-hypertensive effects of imidapril and nifedipine in the treatment of mild-to-moderate essential hypertension. J Int Med Res 2001;29:154-62. (Pubitemid 32655211)
10. Guitard C, Lohmann FW, Alfiero R, et al. Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension. Cardiovasc Drug Ther 1997;11:449-57. (Pubitemid 27367709)
11. de Champlain J, Karas M, Nguyen P, et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998;16:1357-69. (Pubitemid 28408419)
12. Nugent L, Miola S, Walker J. A comparison of enalapril and metoprolol as initial therapy for mild to moderate hypertension. J Clin Pharmacol 1987;27:461-7. (Pubitemid 17143281)
13. Rosenthal J, Haerlin R. Therapeutic assessment of urapidil or angiotensin-converting enzyme inhibition in systemic hypertension. Am J Cardiol 1989;64:25D-9D. (Pubitemid 19206301)
14. Fillastre JP, Letac B, Galinier F, et al. A multicentre double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol 1988;61:81D-5D.
15. Zabludowski J, Rosenfeld J, Akbary M, et al. A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension. Cur Med Res Opin 1988;11:93-106.
16. Whelton A, Eff J, Magner DJ. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992;32:808-15.
17. Fagan TC, Tyler ED, Reitman MA, et al. Sustained-release nicardipine in mild-to-moderate hypertension. Chest 1993;104:427-33. (Pubitemid 23229511)
18. Kassler-Taub K, Littlejohn T, Elliott W, et al; for the irbesartan/losartan study investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53. (Pubitemid 28231457)
19. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000;40:1380-90.
20. Neutel JM, Germino FW, Smith D. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for the treatment of mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2005;6:84-9. (Pubitemid 41699978)
21. Whelton A, Dunne B, Glazer N, et al. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992;6:325-31.
22. Russell JG, Mayhew SR, Humphries IS. Chlorthalidone in mild hypertension - dose response relationship. Eur J Clin Pharmacol 1981;20:407-11. (Pubitemid 11004022)
23. Soghikian K, Bartenbach DE. Influence of dosage and duration of therapy on the rate of response to methylchlothiazide in essential hypertension. South Med J 1977;70:1397-404.
24. Ameling E, de Korte D, Man in't Veld A. Impact of diagnosis of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991;18:752-60.
25. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure and episodic hypertension. Lancet 2010;375:895-905.